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William H. D. Hallett,1 Weiqing Jing,1 William R. Drobyski,2 Bryon D. Johnson1Multiple myeloma is an incurable plasma cell malignancy. Patients who fail conventional therapy are fre-
quently treated with hematopoietic stem cell transplantation (HSCT), which results in reduced tumor bur-
den, but the patients subsequently relapse from sites of chemotherapy-resistant disease. Using the 5T33
murine model of myeloma and a previously successful immunotherapy regimen consisting of autologous
(syngeneic) HSCT and cell-based vaccine administration, we were unable to improve survival of
myeloma-bearing mice. The 5T33 tumor line, similar to malignant plasma cells from myeloma patients, ex-
presses high levels of programmed death receptor ligand-1 (PD-L1), which binds to the inhibitory recep-
tor, PD-1. We observed that T cells from myeloma-bearing mice express high levels of PD-1, which has
also been observed in patients with multiple myeloma. These PD-11 T cells were exhausted and produced
IL-10. Based on these observations, we combined HSCTwith whole-cell vaccination and PD-L1 blockade.
Inhibition of the PD-1/PD-L1 pathway with HSCT and whole-cell vaccination increased the survival of
myeloma-bearing mice from 0% to 40%. These data demonstrate a role for PD-L1 in suppressing immune
responses to myeloma and suggest that blockade of this pathway may enhance immunotherapy for this
disease.
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Multiple myeloma (MM) is an incurable malignancy
characterized by the clonal expansion of malignant
CD1381 plasma cells. MM is the second most common
hematologic malignancy, and approximately 11,000
Americans die of the disease each year [1]. Despite ad-
vances in the treatment of MM using novel therapies
and hematopoietic stem cell transplantation (HSCT),
long-termsurvival is rare andmostpatientsdieof relapse.
Thus, new treatments that have the potential to counter-
act multidrug resistant myeloma cells are needed, and
immunotherapy is an attractive option for this purpose.
Programmed death receptor-1 (PD-1, CD279) is
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hausted T cells result when T cells are unable to clear
an antigen such as in the case of chronic viral stimula-
tion. This situation can also occur as a result of the im-
mune system’s inability to clear a tumor [3].
Engagement of PD-1 by its ligands, either PD-L1
(B7-H1, CD274) or PD-L2 (B7-DC, CD273), results
in the activation of phosphatases that deactivate signals
emanating from the T cell receptor [4]. In addition to
activating inhibitory phosphatases, PD-1 engagement
also upregulates basic leucine ATF-like transcription
factor (BATF) expression, which impairs T cell prolif-
eration and cytokine secretion [5]. Therefore, upregu-
lation of PD-1 and engagement with its ligands can
severely inhibit T cell function.
PD-L1 and PD-L2 have a high degree of homol-
ogy, but they differ in the cells that express them.
PD-L1 is expressed ubiquitously and is upregulated
by interferon (IFN)-g, whereas PD-L2 expression is
restricted to dendritic cells (DCs) and activatedmacro-
phages [6]. Immune dysfunction is associated with
MM [7]. PD-1/PD-L1 interactions may be at least
partly responsible for this state of immune dysfunc-
tion. It has been previously reported that MM cells,
but not normal plasma cells or plasma cells from pa-
tients with monoclonal gammopathy of undetermined
significance (MGUS), express elevated levels of1133
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percentages of T cells in myeloma patients express
PD-1 [9].
An attractive option to treat cancers is through
tumor vaccine therapy. Tumor vaccines often incorpo-
rate the use of DCs pulsed with tumor antigens. This
therapy has the potential to generate robust immune re-
sponses, but clinical efficacy has been limited because
DCs are heterogeneous and consist of both stimulatory
and inhibitory cells [10]. Whole tumor cell–based vac-
cines provide the potential to generate immune re-
sponses when tumor-specific antigens are not known.
These types of vaccines have been shown to provide
effective therapy in multiple experimental models of
cancer therapy [11].
Because of its remarkable similarity to human dis-
ease, we used the murine myeloma tumor model,
5T33, to test the effectiveness of a multifaceted immu-
notherapy approach. This strategy involves the use of
HSCT, T cell transfer, and immediate posttransplan-
tation vaccine administration. For these studies, the
vaccine was generated by transfecting 5T33 tumor to
express the costimulatory proteins CD80 and
CD137L (4-1BB ligand). Similar tumor cell–based ap-
proaches were used to induce robust CD8 T cell-
mediated responses to an experimental neuroblastoma
[12-14]. We hypothesized that this transplantation/
vaccine strategy would significantly improve the
survival of myeloma-bearingmice. However, we found
that overexpression of PD-L1 on the myeloma and
overexpression of its receptor, PD-1, on T cells abro-
gated antitumor responses elicited by the post-
transplantation vaccines, and the increased PD-1
expression correlated with an exhausted CD8 T cell
phenotype. Blockade of PD-L1 by treatment with
a PD-L1-specific antibody increased immunotherapy
efficacy, indicating that the PD-1/PD-L1 pathway
plays an important role in dampening immune recog-
nition of myeloma cells.MATERIALS AND METHODS
Patient Samples
All research involving the use of human samples
was approved by the Medical College of Wisconsin
(MCW) institutional review board, and all participants
provided written informed consent. The 37 sequential
participants were all previously diagnosed with multi-
ple myeloma and were being treated with autologous
hematopoietic stem cell transplantation (further
described in Table 1). All patients were treated with
prophylactic trimethoprim/sulfamethoxazole and acy-
clovir to prevent pneumocystis and herpes virus infec-
tions, respectively. Normal bone marrow cells were
obtained from deidentified discarded quality control
samples.Mice
C57BL/KaLwRij mice were bred in the MCW
Biomedical Resource Center (Milwaukee, WI). A/J
mice were purchased from the Jackson Laboratories
and housed at MCW. This facility is accredited by
the American Association for Accreditation of Labora-
tory Animal Care (AAALAC). The MCW Institu-
tional Animal Care and Use Committee approved all
studies involving animals.
Tumor Cells
The 5T33 murine myeloma cell line was de-
rived from a spontaneous myeloma of C57BL/KaL-
wRij origin [15,16]. Vaccine cells consisted of 5T33
cells that had been transfected to stably express
CD80 and CD137L as previously described [14];
this cell line is designated as 5T33-CD80/137L.
Control 5T33 vaccine cells were stably transfected
with plasmid vectors that did not contain inserted
genes; these cells are referred to as the empty vec-
tor vaccine.
Antibodies and Flow Cytometry
The following monoclonal antibodies (mAbs) and
flow cytometry reagents were obtained from BD Bio-
sciences Pharmingen (San Diego, CA): anti-mouse
CD4 (GK1.5), anti-mouse CD8 (53-6.7), anti-mouse
CD44 (1M7), anti-mouse CD62L (MEL-14), anti-
mouse CD138 (281-2), antimouse PD-1 (J43), antihu-
man CD138 (MI15), antihuman CD3 (HIT3a),
antihuman CD4 (SK3), antihuman PD-L1 (MIH4),
antimouse-Vbetas 2, 3, 4, 5.1/5.2, 6, 7, 8.1/8.2, 8.3,
9, 10b, 11, 12, 13, 14, and 17a, and propidium iodide
staining solution. The following mAbs and reagents
were obtained from eBiosciences (San Diego, CA):
antimouse Foxp3 (FJK-16s), antimouse Tim3
(RMT3-23), antimouse PD-L1 (MIH5), annexin V-
FITC recombinant protein. Cell sorting was per-
formed by the MCW Flow Cytometry Core on a BD
FACS Aria (BD Biosciences, San Jose, CA), and flow
cytometry was performed on a BD FACS Calibur or
a BD LSRII instrument.
Bio-Plex Cytokine Assays
PD-11 and PD-12 CD8 T cells from tumor-
bearing mice and CD8 T cells from na€ıve mice were
cultured in media alone or in the presence of plate-
bound anti-CD3 mAb (clone 145-2C11, BD Biosci-
ences) at 2.5 mg/mL. Culture supernatants were
harvested after 72 hours and stored at 280C until
analysis. A murine multiplex cytokine kit (Bio-Rad,
Hercules, CA) for detecting IL-2, IL-4, IL-6, IL-7,
IL-10, IL-17, tumor necrosis factor (TNF)-a, and
IFN-g was obtained, and the assay performed using
the Bio-Plex suspension array system according to
the manufacturer’s instructions (Bio-Rad). All samples
Table 1. Patient Characteristics*
No. of Patients
Total no. of patients 37
Gender ratio (M:F) 1.6
Age (years), median (range) 61.2, 35-79
No. of monoclonal component isotype
IgG 21
IgA 7
Light chain 4
Other 5
Light chain of the monoclonal component, n
Kappa 26
Lambda 11
Response rate, n
CR 5
CR (near) 2
VGPR 2
PR 27
SD 1
Total no. of samples 81
Mean no. of samples per patient 2.2
Harvest time, n
Pretransplantation 22
Day 30 27
Day 60 18
Day 90 14
SD indicates standard deviation; PR, partial remission; VGPR, very good
partial remission; CR, complete remission.
*Patient information for samples in Figure 9. Thirty-seven sequential pa-
tients who were treated for multiple myeloma at Froedtert Memorial
Lutheran Hospital and had signed informed consents were included in
the study. No selection of patients occurred. Patients had blood drawn
before transplantation and on days 30, 60, and 100 following transplan-
tation.
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using a Bio-Plex protein array reader, and data were
automatically processed and analyzed by Bio-Plex
Manager Software 4.1 using standard curves generated
from recombinant cytokine standards.
Animal Studies
C57BL/KaLwRij mice were injected with 2  106
5T33 cells intravenously. In some studies, the C57BL/
KaLwRij or A/J mice were irradiated with 1100 cGy
total body irridiation (TBI) from a cesium irradiator,
and 1 day later rescued by intravenous injection with
2.5  106-107 syngeneic bone marrow cells and 2 
107 splenocytes or 6  106 purified T cells. The sple-
nocytes served as a source of autologous T cells. Some
groups of mice were then vaccinated subcutaneously
with 2  106 irradiated (5000 rad) 5T33-CD80/137L
cells or empty vector control cells in 300 mL
phosphate-buffered saline (PBS). At the time of vacci-
nation and 2 days following, the mice were given 200
mg of either anti-PD-L1 (9G2) or isotype control
(LTF2) antibodies (BioXcell, West Lebanon, NH).
Antibodies were also added directly to vaccine inocu-
lum at 10 mg/106 cells. Tumor-bearing mice were con-
sidered as moribund and euthanized when they
developed hind-leg paralysis because of development
of paraspinal masses.Statistics
The Student test was used to compare groups for
flow cytometric data, the Overton subtraction was
used to compare PD-L1 expression on CD1381 mye-
loma cells to isotype-labeled fluorescence minus 1
controls, survival curves were compared by log-rank
analysis, and a 1-way analysis of variance (ANOVA)
with a Tukey multiple comparison test was used to ex-
amine PD-1 expression on patient samples over time.
Statistical analyses were performed using Prism 5.0a
software (GraphPad Software, San Diego, CA).
P values\.05 were considered significant.RESULTS
PD-L1 Expression Is Increased on Plasma Cells
in MM Patients
Bone marrow aspirates were obtained from pa-
tients with MM, and MM cells were identified by
CD1381 expression (Figure 1A, 64.9% of light
scatter-gated leukocytes in a representative sample).
These gated CD1381 MM cells were then analyzed
for expression of PD-L1 (thick line, Figure 1B). The
expression of PD-L1 was determined by comparing
the staining intensity with that of cells labeled with
isotype-control antibody (65% by Overton subtrac-
tion). We also examined the PD-L1 expression on all
non-CD1381 cells (CD138-, thin line, Figure 1B). Ex-
pression of PD-L1 on CD138-negative cells was no
greater than background labeling. We also found
that PD-L1 expression is enhanced on CD1381 mye-
loma cells (Figure 1C, black line) but not on
CD1381 cells from healthy adult bone marrow
(Figure 1C, shaded histogram). These data confirm
previously reported data describing PD-L1 expression
on MM cells [8].
The 5T33 Murine MM Model Mimics the PD-L1
Expression Pattern Seen in Clinical Samples
In order to study the effects of PD-L1 expression
on the adaptive immune response to MM in vivo, we
wanted a mouse model that would recapitulate the
clinical observations. We chose to study the 5T33 my-
eloma, which originally arose as a spontaneous malig-
nancy in C57BL/KaLwRij mice. Eventually,
a cultured cell line was derived [15,16], and although
by definition this cell line is no longer stromal-
dependent in culture, when 5T33 cells are injected in-
travenously into syngeneic C57BL/KaLwRij mice the
cells home to the bone marrow (BM) and grow in
a stromal-dependent manner. The disease induced by
5T33 cells remarkably mimics human MM disease in-
cluding preferential localization of tumor cells to the
BM, paraproteinemia, and induction of osteolytic
bone disease [17,18]. We also found that mice with
Figure 1. CD1381 plasma cells in myeloma patients express PD-L1.
(A) Freshly isolated human bone marrow aspirates from patients with
multiple myeloma were analyzed for expression of CD1381 myeloma
cells; a representative example is shown. (B) PD-L1 expression on
CD1381 cells (thick black line) and CD1382 cells (thin black line) and
isotype control staining (gray fill) on the gated CD1381 cells in panel
1136 Biol Blood Marrow Transplant 17:1133-1145, 2011W. H. D. Hallett et al.advanced disease frequently have tumor cells in the
spleen.
Injection of 2 106 5T33 cells intravenously leads
to development of MM, and mice with advanced dis-
ease develop hind leg paralysis approximately 35 days
after tumor cell injection as a result of spinal compres-
sion from paraspinal masses. We sought to determine
the tumor’s effect on the immune system by analyzing
splenocytes frommice that had developed hind-leg pa-
ralysis. Similar to human MM, the 5T33 line could be
identified by the expression of CD138, and these cells
uniformly expressed high levels of PD-L1 (Figure 2A).
The expression of PD-L1 and CD138 are similar to
levels on cells cultured in vitro, and the expression of
PD-L1 could be elevated by culturing the cells with in-
terferon-g (IFN-g) (data not shown). Percentages of
myeloma cells observed in spleens were variable, but
typically 10% to 15% myeloma cells were observed
(Figure 2B). In contrast, high percentages of tumor
cells were always observed in BM samples from mice
with advanced disease (Figure 3B). Importantly, only
small numbers of CD1381 cells were observed in
mice not injected with 5T33 MM cells (Figure 2B,
nontumor bearing).Increased Percentages of PD-11T cells Are Seen
in Mice with Advanced Myeloma, and the PD-11
T Cells Are Limited to Areas of Local Tumor
Accumulation
Benson and colleagues [9] noted in a recent publi-
cation that T cells in the peripheral blood of MM pa-
tients have increased expression of PD-1, the receptor
for PD-L1. We examined whether PD-1 expression is
similarly increased on T cells in the spleens of mice
with myeloma. In nontumor-bearing mice, PD-1 was
expressed on relatively low percentages (5%-10%)
of splenic CD8 and CD4 T cells (Figure 2C-F, nontu-
mor bearing). However, moribundmice with advanced
MM expressed elevated levels of PD-1 on both CD8
(20%-60%) and CD4 (18%-40%) T cells. Interest-
ingly, percentages of PD-11 T cells correlated with
the amount of tumor burden observed. These data
demonstrate that similar to MM patients, PD-1 ex-
pression is increased on T cells in 5T33-bearing
mice. The data also suggests that the 5T33 tumor
may have a role in controlling the expression of
PD-1 on the T cells, as there is a correlation between
tumor burden (ie, percentages of tumor cells present)
and percentages of PD-11 T cells.
Based on the observation that PD-1 expression is
increased on T cells in the peripheral blood of MMA are compared. The PD-L1 expression is representative of more
than 5 samples. (C) PD-L1 expression on CD1381 cells from a multiple
myeloma patient (black line) are compared with PD-L1 expression on
CD1381 cells from a normal healthy adult (gray fill).
Figure 2. Murine 5T33 myeloma cells express high levels of PD-L1, and T cells from myeloma-bearing mice express elevated levels of PD-1. (A)
Nontumor-bearing and moribund tumor-bearing mice were analyzed for the presence of CD1381PD-L11 5T33 myeloma cells in their spleens. The
percentage of CD1381 cells from na€ıve mice and tumor-bearing mice is shown. PD-1 expression on (B) CD8 and (C) CD4 T cells from the same
mice in panel A is shown. Average percentages of (D) CD1381 cells, (E) PD-11 CD8 T cells, and (F) PD-11 CD4 T cells were calculated. Each bar rep-
resents the average of more than 10 mice, and statistical comparisons were determined using the t test.
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myeloma-bearing mice were analyzed for PD-1 ex-
pression. However, unlike clinical samples, few
peripheral blood CD8 T cells (\3%) in myeloma-
bearing mice expressed PD-1 (Figure 3A, right panel).
This lack of PD-1 expression correlated with a lack of
CD1381 cells in the peripheral blood (Figure 3A, left
panel). Other organs, based on previously identified
locations of CD1381 cells [19] in the same animal
were also examined for the presence of PD-11 CD8
T cells. In the bone marrow, where the tumor prefer-
entially migrates to after injection, high percentages of
CD8 T cells expressing PD-1 were seen (Figure 3B).
Lymph nodes were similar to peripheral blood in
that no MM cells were detected and there were rela-
tively few PD-11 CD8 T cells present (Figure 3C).
The spleen had increased percentages of PD-11
CD8T cells, which correlated to themoderate amount
of tumor cells observed in this tissue (Figure 3D).Similar PD-1 levels were also observed on CD4T cells
(data not shown). These data provide additional sup-
port that MM tumor cells selectively upregulate PD-
1 on resident T cells.PD-11 T Cells in Tumor-Bearing Mice Have
an Effector Memory Penotype and Appear
to Be Undergoing Apoptosis
T cells from tumor-bearing and nontumor-
bearing mice were next analyzed for expression of
activation markers. Generally, na€ıve T cells are de-
fined as CD44lowCD62L1, central memory T cells
as CD44hiCD62L1, and effector memory T cells as
CD44hiCD62L2. Although CD8 T cells from resting
nontumor-bearing mice had a relatively normal
CD44/CD62L phenotypic profile, CD8 T cells from
tumor-bearing mice were skewed toward an activated
effector memory phenotype (Figure 4A). When the
Figure 3. PD-11 T cells are localized to the same tissue sites as myeloma. A single representative mouse with an advanced tumor-burden was eutha-
nized and (A) blood, (B) bone marrow, (C) an inguinal lymph node, and (D) the spleen were harvested and analyzed for expression of tumor cells (PD-
L11 and CD1381) and PD-1 expression on CD8 T cells. The data are representative of more than 3 experiments.
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and PD-12 T cells from tumor-bearing mice, PD-
12 CD8 T cells had elevated percentages of cells
with a central memory phenotype (22%), but there
were also increased percentages of cells with an effec-
tor memory phenotype (Figure 4B, left panel). PD-11
CD8 T cells almost exclusively had an effector mem-
ory phenotype (81%), with few remaining na€ıve cells
(Figure 4B, right panel). These data suggest that the
PD-11 CD8 T cells have been previously activated.
PD-12 and PD-11 CD8 T cells from tumor-
bearingmicewere also analyzedbyflowcytometry after
staining with annexin V and propidium iodide to deter-
mine if they were apoptotic. For comparison, CD8
T cells from nontumor-bearing mice were also ana-
lyzed. CD8 T cells from nontumor-bearing mice and
PD-12 CD8 T cells from tumor-bearing mice bound
little or no annexin V (Figure 5A and B). In contrast,
nearly 50% of PD-11 CD8 T cells from tumor-
bearingmice bound annexin V, and approximately 10%
of the cells were also propidium iodide-positive
(Figure 5C).Thus, thePD-11CD8Tcells inmyeloma-
bearing mice appeared to be undergoing apoptosis.PD-11CD8 T Cells in Tumor-Bearing Mice Have
an Exhausted Phenotype and Express Tim3
To determine if the PD-11 T cells in tumor-
bearing mice represent exhausted or activated cells,
or other possible phenotypes, an in vitro functional ex-
periment was conducted. Sorted CD81PD-11 and
CD81PD-12 cells from tumor-bearing mice, and
sorted CD81 cells from nontumor-bearing mice werecultured in media alone or stimulated with plate-
bound anti-CD3 (2C11) for 72 hours. Culture super-
natants were collected and analyzed for cytokine
production using a multiplex platform (see Materials
and Methods for details). Unstimulated T cells did
not produce detectable levels of any of the cytokines
examined (Figure 6A-D). Upon stimulation with
anti-CD3, differences were seen in the cell cytokine
profiles. Tumor-bearing PD-12 CD8 T cells and
nontumor-bearing CD8 T cells produced IL-2, but
tumor-bearingPD-11Tcells did not (Figure 6A). Sim-
ilar results were observed for IFN-g (Figure 6C) and
TNF-a (Figure 6B). However, opposite effects were
observed with IL-10 in that only PD-11CD81 T cells
from tumor-bearing mice produced IL-10 in response
to anti-CD3 stimulation (Figure 6D).
Recent data has shown that PD-11Tim31-posi-
tive T cells represent exhausted T cells that produce
IL-10 [20]. Based on the IL-10 production by PD-
11 CD8 T cells from tumor-bearing mice, T cells
from na€ıve and tumor-bearing mice were examined
for expression of Tim3. CD8 T cells from na€ıve
mice express low constitutive levels of PD-1, and
very few cells expressed Tim3 (Figure 6E). In contrast,
nearly 50% of PD-11 CD8 T cells from tumor-
bearing mice were Tim31, and the percentages of
PD-11Tim31 CD8 T cells in tumor-bearing mice
were significantly higher than percentages of these
cells in nontumor-bearing mice (Figure 6E and F).
We hypothesize that these IL-10-producing PD-
11Tim31 CD8 T cells are exhausted cells because of
their lack of inflammatory cytokine (IL-2, IFN-g,
and TNF-a) production.
Figure 4. PD-11 CD8 T cells have an effector phenotype. (A) Percentages of splenic CD8 T cells with a na€ıve (CD44lowCD62L1), central memory
(CD44hiCD62L1) and effector memory (CD44hiCD62L2) phenotype are shown for a nontumor-bearing mouse and a mouse with advanced myeloma.
(B) CD8 T cells from a myeloma-bearing mouse were separated based on their expression of PD-1, and the PD-12 and PD-11 cells were analyzed for
CD44 and CD62L expression. Data are representative of more than 10 mice.
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Cells and Facilitates the Expansion of
Regulatory T Cells and Myeloid-Derived
Suppressor Cells
Recent data indicates that NK cells in patients with
MM express PD-1 [9]. To determine if NK cells in
myeloma-bearing mice similarly express increased
levels of PD-1, NK cells in mice with advanced mye-
loma (ie, they were moribund) were analyzed. A signif-
icant increase in the expression of PD-1 was observed
on NK cells in myeloma-bearing mice compared
with NK cells in nontumor-bearing (na€ıve) mice
(Figure 7A, P\ .05).
Increased numbers of Foxp31 regulatory T cells
have been observed in both myeloma patients [21,22]
and myeloma-bearing mice [23]. In nontumor-bearing
C57BL/KaLwRij mice, approximately 12% of CD4 T
cells express Foxp3 (Figure 7B, naive). However, more
than 27% of CD4 T cells in mice with advanced mye-
loma expressed Foxp3 (Figure 7B, tumor). A significant
expansion of cells with amyeloid-derived suppressor cell
(MDSC) phenotype was also seen in myeloma-bearingmice (Figure 7C, P\ .05). These results suggest that
multiple inhibitory pathways could play a role in sup-
pressing the generation of immune responses to mye-
loma.
PD-L1 Blockade Improves the Efficacy
of Posttransplantation Immunotherapy
for Established Myeloma
Amyeloma immunotherapy regimen that incorpo-
rates syngeneic HSCT, T cell adoptive transfer, and
immediate posttransplantation vaccine administration
was developed (Figure 8A). Mice were injected with 2
 106 5T33 MM cells intravenously (day 28). Seven
days later (day 21), the mice were given lethal TBI
(1100 cGy) and then rescued the following day (day
0) with 2.5  106 C57BL/KaLwRij BM cells plus 2
 107 splenocytes from the same donors. On days 3,
10, and 17 after transplantation, vaccines were admin-
istered subcutaneously in the form of 2  106 irradi-
ated 5T33-CD80/137L cells or 5T33 cells stably
transfected with empty vectors. On days 3, 5, 10, 12,
17, and 19, some mice were treated with either
Figure 5. PD-11CD8Tcells inmyeloma-bearingmice areundergoing ap-
optosis. (A) The apoptotic profiles of CD8 cells from a nontumor-bearing
mouse, and (B) PD-12 and (C) PD-11 CD8 T cells from a tumor-bearing
mouse, are depicted. Percentages of healthy (annexin V2, propidium
iodide2), early apoptotic (annexinV1, propidium iodide2), andnecrotic (an-
nexin V1, propidium iodide1) cells were determined using fluorescent-
minus-one (FMO) controls. Data are representative of 2 individual
experiments.
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ment of myeloma-bearing transplant recipients with
control antibody (rIgG), anti-PD-L1, the empty vec-
tor vaccine alone, or the CD80/CD137L vaccine alone
did not provide any therapeutic effect, as all mice died
from tumor progression (Figure 8B). A modest, but
significant (P\ .05), impact on survival was observed
when the empty vector vaccine was given in combina-
tion with anti-PD-L1. The combination of CD80/
CD137L vaccine cells and anti-PD-L1 improved
100-day survival to approximately 40% (P \ .05 vs
all other groups). Treatment with a PD-1-specific an-
tibody (J43) did not provide any additional survival ad-
vantage over that achieved with anti-PD-L1 treatment
(data not shown).
To examine whether HSCT contributes to the im-
munotherapeutic effects observed in Figure 8B, non-
transplanted mice were injected with 5T33 cells and
subjected to the same treatment regimen (Figure 8C).
In the nontransplantation setting, vaccination and
anti-PD-L1 administration failed to provide any sur-
vival advantage over nontreated controls (Figure 8D).
Together, the data in Figure 8 demonstrate that: (1)
HSCT is an important component of our myelomaimmunotherapy approach, and (2) posttransplantation
vaccine administration can be effective in treating es-
tablished myeloma, but the PD-1/PD-L1 pathway
must be blocked in order for it to be effective.T Cells in MM Patients Express PD-1 Early
after Autologous HSCT
To determine whether the observations made in
the mouse model (Figure 8B) could potentially trans-
late back to the clinic, we examined whether T cells
in MM patients treated with autologous HSCT ex-
press PD-1. Various percentages of freshly isolated pe-
ripheral blood CD4 (CD31CD41) and CD8
(CD31CD42) T cells from MM patients were found
to express PD-1 (n5 37); Figure 9A shows the expres-
sion of PD-1 (dot plots) compared with isotype con-
trols (underlying contour plots) for both CD8 and
CD4 T cells in both peripheral blood and bone mar-
row of representative patients before transplantation.
In 1 representative patient, 52% of CD8 and 41% of
CD4 T cells in peripheral blood expressed PD-1,
whereas in another representative patient, 55% of
CD8 and 57% of CD4 T cells in bone marrow ex-
pressed PD-1. Expression of PD-1 on peripheral
blood CD8 (Figure 9B) and CD4 (Figure 9C) T cells
was also examined at days 30, 60, and 100 posttrans-
plantation as well as pretransplantation (PreT). At
day 30 after transplant, percentages of PD-11 T cells
were significantly increased over pretransplantation
levels (P\.05).Therewas then a significant downregu-
lation of PD-1 at both day 60 and day 90 inCD8 as well
as CD4 T cells. In the murine model of autologous
(syngeneic) transplantation, there is also an increase
of PD-1 expression by T cells that occurs 2 to 3 weeks
following transplantation that then returns to basal
levels around day 30 (data not shown), which is because
of homeostatic proliferation [24]. These data indicate
that PD-1 is present on patient T cells early following
autologous HSCT, and they suggest that T cell re-
sponses to myeloma could be dampened if PD ligands
are encountered during this time period. We also
sought to determine if a similar phenomenon occurs
in our murine model (Figure 9D). Tumor-free
C57BL/KaLwRijmicewere lethally irradiated and res-
cued with syngeneic bone marrow and splenocytes,
similar to the experiment described in Figure 8A. At
7-day intervals after transplantation, PD-1 expression
on T cells was determined by flow cytometric analysis.
We observed a dramatic increase in PD-1 levels, pre-
sumably caused by homeostatic proliferation, early af-
ter transplant that gradually returned to near basal
levels. In order to verify that this effect was not strain
specific, we also examined PD-1 expression in A/J
mice. A/J mice were given lethal TBI followed by 107
BMand 6 106T cells, and PD-1 expressionwasmon-
itored on CD8 T cells. Although the PD-1 expression
Figure 6. PD-11CD8 T cells do not produce pro-inflammatory cytokines and express the exhausted T cell marker Tim3. PD-11 and PD-12CD81 T
cells from tumor-bearing mice and CD81 T cells from nontumor-bearing mice were sorted and cocultured for 72 hours in either media (No Stim) or in
media with plate-bound anti-CD3 antibodies (Anti-CD3). Culture supernatants were harvested and the production of (A) IL-2, (B) TNF-a, (C) IFN-g,
and (D) IL-10 were measured by Bio-Plex. The cytokine data is representative of 2 independent experiments. (E) CD81 T cells from nontumor-bearing
mice and tumor-bearing mice were analyzed for the expression of PD-1 and Tim3. (F) The percent of PD-11Tim31 CD8 T cells was quantitated. The
data are from 3 mice and are representative of 2 independent experiments.
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crease and subsequent decrease in PD-1 levels follow-
ing autologous transplantation is similar to what we
observed clinically, although the timing of return
toward baseline levels was much quicker than that ob-
served in the patient samples (Figure 9B and C). These
data demonstrate thatmurineT cells, similar to human
T cells, express PD-1 during the time when posttrans-
plant homeostatic proliferation is occurring.DISCUSSION
In this study, we have shown that T cells from
myeloma-bearing mice upregulate the expression of
PD-1 in response to multiple myeloma. These PD-
11 CD8 T cells appear to have been activated; yet,
their inability to clear the tumor has resulted in theirdevelopment into exhausted effector cells. These ex-
hausted CD8 cells lack the ability to produce IL-2,
TNF-a, or IFN-g, but they do produce IL-10. Addi-
tionally, they appear to be undergoing apoptosis.
Blockade of PD-L1 during vaccine administration re-
sulted in improved vaccine efficacy, suggesting that ef-
fective antitumor immunity for myeloma is possible
once this inhibitory pathway is blocked.
The expression of PD-L1 on malignant plasma
cells, but not on CD1381 cells from normal volunteers
or patients with the premyeloma conditionMGUS has
been previously demonstrated [8]. The expression of
PD-L1 by many tumors has been reported and it is as-
sociated with a worse prognosis in renal carcinoma
[25]. It has also been reported that blocking PD-L1
improves the efficacy of tumor vaccines [26-29].
These previous observations, combined with our
own clinical data (Figure 1), led us to hypothesize
Figure 7. Myeloma-bearing mice have elevated PD-1 expression on NK cells, and elevated numbers of regulatory T cells and myeloid-derived suppres-
sor cells. (A) Percentages of PD-11NK cells (NKp461CD32) from na€ıve (nontumor-bearing) and tumor-bearing mice are shown in the left and center
panels, and are quantitated in the right panel. (B) The percentages of regulatory T cells (CD41Foxp31) from na€ıve (left panel) and tumor-bearing (middle
panel) mice are shown, and are quantitated in the right panel. (C) The percentages of CD11b1Gr-11 myeloid-derived suppressor cells (MDSC) from
na€ıve (left panel) and tumor-bearing (middle panel) mice are shown, and are quantitated in the right panel. Quantitated data are combined from more
than 5 mice per group, and the data are representative of more than 3 experiments. Statistical comparisons were performed using the t test.
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prove vaccine-based immunotherapy for multiple my-
eloma. To test this hypothesis, we ‘‘validated’’ the
clinical observations in a murine myeloma model,
and incorporated the use of a multifaceted immuno-
therapy approach to treat established disease. Our hy-
pothesis was correct, as PD-L1 blockade significantly
improved immunotherapy efficacy (Figure 8). An ar-
gument might be made that the PD-L1 blockade ap-
proach would only apply to a tumor cell–based
vaccine, because the tumor cells expresses PD-L1.
However, many different cell types express PD-L1,
and we believe that this approach would also apply to
DC-based vaccines, as DCs are known to upregulate
both PD-L1 and PD-L2 when they are activated
[30]. Because DCs are important for generating
antigen-specific immune responses, it is possible that
any vaccine-based therapies could benefit from block-
ade of the PD-1/PD-L1 pathway.Two blocking antibodies directed against PD-1
have been tested in cancer patients: MDX-1106 and
CT-011. These antibodies have generated encourag-
ing results and are well tolerated [9,31,32]. Our
preclinical data advocates for future testing of these
antibodies in myeloma patients given some form of
active immunotherapy. A recent study by Benson
et al. [9] shows that NK cells in patients with MM
have elevated PD-1 expression. In this study, they ob-
served that the CT-011 antibody enhances NK cell-
mediated trafficking as well as IFN-g and Granzyme
B production in response to MM cells. Our study
also shows evidence for PD-1 upregulation on NK
cells in murine MM. Although we currently do not
know the impact this expression has on NK cell func-
tion, it provides a unique model for testing the in vivo
role of PD-1 on NK cell function in MM.
Our observation that relatively large numbers of
PD-11 T cells are present in the tumor
Figure 8. PD-L1 blockade improves the efficacy of posttransplant vaccine-based immunotherapy for myeloma, but it has no effect in non-transplanted
mice. (A) Experimental design for transplanted tumor-bearing mice. (B) Survival curves are shown for transplanted mice treated with vaccines and anti-
PD-L1 mAb or control antibodies. Specifically, mice were injected with 2106 5T33 cells i.v., lethally irradiated (1100 cGy TBI) 7 days later, and then
rescued with 2.5106 BM cells plus 2107 splenocytes. The transplanted mice were then either given control antibody alone (rIgG), anti-PD-L1 mAb
alone (anti-PD-L1), an empty vector vaccine plus control antibody (Empty Vector Vaccine 1 rIgG), an empty vector vaccine plus anti-PD-L1 (Empty
Vector Vaccine1 anti-PD-L1), 5T33-CD80/137L vaccine cells plus control antibody (CD80/CD137LVaccine1 rIgG), or 5T33-CD80/137L vaccine cells
plus anti-PD-L1 (CD80/CD137LVaccine1 anti-PD-L1). The asterisks represent P\0.05 as determined by the log-rank test. Data are combined from
two independent experiments, and are representative of four experiments. (C) Experimental design for non-transplanted tumor-bearing mice. (D)
Survival curves are shown for non-transplanted mice injected with 2106 5T33 cells i.v., and either given no further treatment (No Tx) or treated
with 5T33-CD80/137L vaccine cells plus anti-PD-L1 at the indicated time points. Data are combined from 2 experiments.
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study [3,30]. PD-1 expression on ‘‘tumor-infiltrating’’
CD8 T cells in our model identifies T cells with an ex-
hausted phenotype and impaired effector function.
The mechanism involved in myeloma-induced PD-1
upregulation on T cells is currently under investiga-
tion, but our data suggests that the myeloma cells
induce PD-1 expression to inhibit a potential antitu-
mor immune response. It is interesting that although
the 5T33 myeloma expresses only MHC class I mole-
cules (no MHC class II), PD-1 expression is induced
on both CD8 and CD4 T cells. This implicates the in-
volvement of DCs or other antigen-presenting cells in
the upregulation of PD-1 on T cells.
In the hematopoietic transplant setting, blocking
the PD-1/PD-L1 pathway may be particularly impor-
tant for generating effective immune responses. Nota-
bly, PD-L1 blockade and vaccination improved
survival in transplanted mice but not in nontrans-
planted mice (Figure 8B vs 8D). The reason for this
difference is unclear, but increased expression of PD-
1 on T cells occurs during lymphopenia-induced
homeostatic proliferation in mice [24], and this also
appears to occur after autologous transplantation in
patients (Figure 9B and C) as well as in mice
(Figure 9D and E). The increased expression of
PD-1 during homeostatic expansion makes it difficultto determine the influence of residual tumor cells on
PD-1 expression posttransplantation. But the PD-11
T cells undergoing homeostatic expansion can be tran-
siently inhibited by PD-L ligation, they fail to produce
IFN-g or TNF-a, and they disappear from the host,
presumably by apoptosis from a failure to respond to
survival signals [24]. The ligation of PD-1 is known
to activate phosphatases that reduce signaling through
the T cell receptor (TCR) [33]. It is noteworthy that
the splenocytes used in these studies were from na€ıve
mice, not from tumor-bearing donors. Thus, it is pos-
sible that our therapy is effective because the PD-1 ex-
pression on donor T cells is transient, and these cells
will regain functional activity. PD-1 expression on T
cells induced by myeloma may be fundamentally dif-
ferent and indicate cells that are devoid of antitumor
function. Studies examining the functional status of
T cells with tumor-induced PD-1 expression, and
the ability to restore functional activity to these ‘‘ex-
hausted’’ cells, are under way. It would also be worth-
while to know if the PD-1 expression induced by
homeostatic proliferation inhibits responses to PD-
L1-expressing myeloma cells, if PD-1 expression in-
duced by tumor cells plays a role in this setting, or if
both are important.
A limitationofour study is the lackof a known tumor
antigen(s) that could be used to track tumor-specific
Figure 9. Peripheral blood CD4 and CD8 T cells in multiple myeloma patients express PD-1 after autologous HSCT. (A) PD-1 expression was analyzed
on CD8 and CD4 T cells in a myeloma patient before transplantation. Representative expression of PD-1 on peripheral blood CD8 and CD4 T cells, as
well as pretransplant bone marrow resident CD8 and CD4 T cells in myeloma patients is shown. (B) Expression of PD-1 on CD8 T cells or (C) CD4 T
cells before transplantation (PreT) and 30, 60, and 100 days after autologous hematopoietic stem cell transplantation. The PD-1 expression profiles in
panels B and C represent data from 37 patients. (D) PD-1 expression on CD8 T cells from tumor-free C57BL KaLwRij mice before transplantation and at
7-day intervals following syngeneic transplantation of 2.5 106 BM and 2 107 splenocytes are shown. Data are from 3 to 4mice per group. (E) A/J mice
were treated with a lethal dose of TBI on day 21. On day 0, the mice were injected with 107 syngeneic BM cells supplemented with 6  106 T cells.
Spleens were collected on days 7, 14, 21, 28, and 45 after HSCT, and the expression of PD-1 on CD8 T cells was analyzed. The data is combined
from 2 to 3 experiments, with 6 to 9 total mice per group. Results were compared using the Student t test (*P\.05, **P\.01, compared with na€ıve
nontransplanted control mice).
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early immune response, as PD-1 upregulation was only
observed once substantial tumor burdens had occurred.
This makes investigating the early events very challeng-
ing.One issueweare in theprocessof investigating is the
relative importance of the PD-1 pathway during both
the initiation and effectorphases of the antimyeloma im-
mune response. In a prophylactic vaccine system, in
which mice were vaccinated before myeloma challenge,
vaccine cells only facilitated tumor rejection if the vac-
cines were administered at the same time as anti-PD-
L1 blocking antibodies (data not shown). These data
demonstrate that the PD-1 pathway can inhibit the
initiation phase of the immune response, but we donot currently knowwhat, if any, effects PD-L1 blockade
would have during the effector phase.
In summary, we report that PD-1 is expressed on
a relatively large number of T cells in myeloma-
bearing mice but only in sites of tumor accumulation.
The PD-11 CD8 T cells display an exhausted pheno-
type and have impaired effector function compared
with PD-12 CD8 T cells. Blockade of the PD-1 path-
way with monoclonal antibodies directed against PD-
L1 increased the survival of myeloma-bearing mice
when combined with cell-based vaccine immediately
after HSCT. These findings suggest that targeting
the PD-1 pathway could result in improved immuno-
therapy for multiple myeloma.
Biol Blood Marrow Transplant 17:1133-1145, 2011 1145PD-L1 Blockade in MyelomaACKNOWLEDGMENTS
Financial disclosure:This research was supported by
the Midwest Athletes Against Childhood Cancer
Fund, Milwaukee, WI, NIH Grant HL064603, and
by a fellowship grant from the Medical College of
Wisconsin Cancer Center. The authors acknowledge
Megan Whitaker and Laura McOlash for outstanding
technical support, Kristen Barr for experimental assis-
tance, Dr. JeffWoodliff in the MCWFlow Cytometry
Core for cell separations, Dr. CalvinWilliam for use of
flow cytometric equipment, and Dr. Jill Gershan and
Dr. Bruce Blazar for helpful discussions. The authors
also thank NIH HL064603, the MCW Cancer Cen-
ter, and theMidwest Athletes Against Childhood Can-
cer for financial support.REFERENCES
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer sta-
tistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its li-
gands in tolerance and immunity. Annu Rev Immunol. 2008;26:
677-704.
3. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor
antigen-specific CD8 T cells infiltrating the tumor express
high levels of PD-1 and are functionally impaired. Blood. 2009;
114:1537-1544.
4. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;
229:114-125.
5. Quigley M, Pereyra F, Nilsson B, et al. Transcriptional analysis
of HIV-specific CD81 T cells shows that PD-1 inhibits T cell
function by upregulating BATF. Nat Med. 2010;16:1147-1151.
6. Tseng SY,OtsujiM,Gorski K, et al. B7-DC, a new dendritic cell
molecule with potent costimulatory properties for T cells. J Exp
Med. 2001;193:839-846.
7. Pratt G, Goodyear O, Moss P. Immunodeficiency and immuno-
therapy in multiple myeloma. Br J Haematol. 2007;138:563-579.
8. Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from mul-
tiple myeloma patients express B7-H1 (PD-L1) and increase ex-
pression after stimulation with IFN-{gamma} and TLR ligands
via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood.
2007;110:296-304.
9. Benson DM, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis
modulates the natural killer cell versus multiple myeloma effect:
a therapeutic target for CT-011, a novel monoclonal anti-PD-1
antibody. Blood. 2010;116:2286-2294.
10. Andrews DM, Maraskovsky E, Smyth MJ. Cancer vaccines for
established cancer: how to make them better? Immunol Rev.
2008;222:242-255.
11. Rousseau RF, Brenner MK. Vaccine therapies for pediatric ma-
lignancies. Cancer J. 2005;11:331-339.
12. Johnson BD, Gershan JA, Natalia N, et al. Neuroblastoma cells
transiently transfected to simultaneously express the co-
stimulatorymoleculesCD54,CD80,CD86, andCD137Lgener-
ate antitumor immunity inmice. J Immunother. 2005;28:449-460.
13. Johnson BD, Yan X, Schauer DW, Orentas RJ. Dual expression
of CD80 and CD86 produces a tumor vaccine superior to single
expression of either molecule. Cell Immunol. 2003;222:15-26.
14. Yan X, Johnson BD, Orentas RJ. Induction of a VLA-2
(CD49b)-expressing effector T cell population by a cell-based
neuroblastoma vaccine expressing CD137L. J Immunol. 2008;
181:4621-4631.
15. Manning LS, Berger JD, O’Donoghue HL, Sheridan GN,
Claringbold PG, Turner JH. A model of multiple myeloma:culture of 5T33 murine myeloma cells and evaluation of tumor-
igenicity in the C57BL/KaLwRij mouse. Br J Cancer. 1992;66:
1088-1093.
16. Radl J, Croese JW, Zurcher C, Van den Enden-VieveenMH, de
LeeuwAM. Animalmodel of human disease.Multiple myeloma.
Am J Pathol. 1988;132:593-597.
17. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K.
The 5TMM series: a useful in vivo mouse model of human mul-
tiple myeloma. Hematol J. 2000;1:351-356.
18. Vanderkerken K,De RaeveH, Goes E, et al. Organ involvement
and phenotypic adhesion profile of 5T2 and 5T33myeloma cells
in the C57BL/KaLwRij mouse. Br J Cancer. 1997;76:451-460.
19. Alici E, Konstantinidis KV, Aints A, Dilber MS, Abedi-
Valugerdi M. Visualization of 5T33 myeloma cells in the
C57BL/KaLwRij mouse: establishment of a new syngeneic mu-
rine model of multiple myeloma. Exp Hematol. 2004;32:
1064-1072.
20. Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim-3
and PD-1 in CD8 T-cell exhaustion during chronic viral infec-
tion. Proc Natl Acad Sci USA. 2010;107:14733-14738.
21. Feyler S, von Lilienfeld-Toal M, Jarmin S, et al. CD4(1)
CD25(1)FoxP3(1) regulatory T cells are increased whilst
CD3(1)CD4(2)CD8(2)alphabetaTCR(1) Double Negative
T cells are decreased in the peripheral blood of patients with
multiple myeloma which correlates with disease burden. Br J
Haematol. 2009;144:686-695.
22. Beyer M, Kochanek M, Giese T, et al. In vivo peripheral expan-
sion of naive CD41CD25high FoxP31 regulatoryT cells in pa-
tients with multiple myeloma. Blood. 2006;107:3940-3949.
23. Laronne-Bar-On A, Zipori D, Haran-Ghera N. Increased regu-
latory versus effector T cell development is associated with thy-
mus atrophy in mouse models of multiple myeloma. J Immunol.
2008;181:3714-3724.
24. Lin S-J, Peacock CD, Bahl K,Welsh RM. Programmed death-1
(PD-1) defines a transient and dysfunctional oligoclonal T cell
population in acute homeostatic proliferation. J Exp Med.
2007;204:2321-2333.
25. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1
is associated with poor prognosis in renal cell carcinoma patients
with long-term follow-up. Cancer Res. 2006;66:3381-3385.
26. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves
myeloid dendritic cell-mediated antitumor immunity. Nat
Med. 2003;9:562-567.
27. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade aug-
ments adoptive T-cell immunotherapy for squamous cell carci-
noma. Cancer Res. 2003;63:6501-6505.
28. He YF, Zhang GM, Wang XH, et al. Blocking programmed
death-1 ligand-PD-1 interactions by local gene therapy results
in enhancement of antitumor effect of secondary lymphoid tis-
sue chemokine. J Immunol. 2004;173:4919-4928.
29. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and
PD-1 by monoclonal antibodies potentiates cancer therapeutic
immunity. Cancer Res. 2005;65:1089-1096.
30. Breton G, Yassine-Diab B, Cohn L, et al. siRNA knockdown of
PD-L1 and PD-L2 in monocyte-derived dendritic cells only
modestly improves proliferative responses to Gag by CD8(1)
T cells from HIV-1-infected individuals. J Clin Immunol.
2009;29:637-645.
31. Brahmer JR, Drake CG,Wollner I, et al. Phase I study of single-
agent anti-programmed death-1 (MDX-1106) in refractory solid
tumors: safety, clinical activity, pharmacodynamics, and immu-
nologic correlates. J Clin Oncol. 2010;28:3167-3175.
32. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety
and pharmacokinetic study of CT-011, a humanized
antibody interacting with PD-1, in patients with advanced
hematologic malignancies. Clin Cancer Res. 2008;14:
3044-3051.
33. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-
1 receptors inhibit T-cell activation by distinct mechanisms.Mol
Cell Biol. 2005;25:9543-9553.
